Sarepta exchanges $291M of 1.25% notes due 2027 for 4.875% notes due 2030 plus $31.6M cash

Sarepta Therapeutics, Inc.

Exchanges $291.4M principal of 1.25% convertibles due 2027 for same principal of 4.875% convertibles due 2030, plus $31.6M in cash.
New 4.875% notes are part of same series as $602M issued Aug 2025; post-exchange total $893.4M outstanding.
Approximately $158.6M of existing 1.25% notes will remain outstanding with unchanged terms.
Placement agent intends to buy ~691,000 SRPT shares in private transactions from exchanging investors at a discount.
Exchange expected to close on or about December 18, 2025, subject to customary closing conditions.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Sarepta Therapeutics, Inc. issued approximately $291.4 million in aggregate principal amount of 4.875% Convertible Senior Notes due 2030 of convertible note to certain holders of its 1.25% Convertible Senior Notes due 2027, including the Michael A. Chambers Living Trust for approximately $291.4 million in aggregate principal amount of Existing Convertible Notes and approximately $31.6 million in cash.

Security: convertible note
Shares: approximately $291.4 million in aggregate principal amount of 4.875% Convertible Senior Notes due 2030
Purchaser: certain holders of its 1.25% Convertible Senior Notes due 2027, including the Michael A. Chambers Living Trust
Consideration: approximately $291.4 million in aggregate principal amount of Existing Convertible Notes and approximately $31.6 million in cash

Exact text from the filing

a member of the Company’s board of directors. Under the terms of the Exchange Agreements, the holders party thereto have agreed to exchange with the Company approximately $291.4 million in aggregate principal amount of Existing Convertible Notes held by them for (i) approximately $291.4 million in aggregate principal amount of 4.875% Convertible Senior Notes due

View on SEC.gov

Browse all equity issuances →

Sarepta Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-315032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.